|Bid||1.80 x 13200|
|Ask||1.85 x 600|
|Day's range||1.80 - 1.90|
|52-week range||1.55 - 5.75|
|PE ratio (TTM)||N/A|
|Earnings date||30 Oct 2017 - 3 Nov 2017|
|Forward dividend & yield||N/A (N/A)|
|1y target est||4.00|
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.
Merck's (MRK) anti-PD-1 therapy, Keytruda, gains approval in Japan for previously-treated patients with bladder cancer. Keytruda can now be indicated for four types of cancer in Japan.
Independent Data Monitoring Committee endorses evaluation of Actinium's (ATNM) lead pipeline candidate, Iomab-B, for a pivotal phase III SIERRA study.
The Redwood City, California-based company said it had a loss of 28 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
Goldberg Law PC, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AcelRx Pharmaceuticals, Inc. .
AcelRx (ACRX) receives CRL for its opioid painkiller, Dusvia. The FDA has requested resubmission with additional safety data and recommended changes to drug administration.
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.
AcelRx Pharmaceuticalssaw its shares rise nearly 20% on the day in anticipation of an FDA approval for AcelRx's pain medication Dsuvia.